Business Wire

CA-FORESCOUT

14.9.2023 14:01:27 CEST | Business Wire | Press release

Share
U.S. Department of Defense Awards Forescout New Comply-to-Connect Contract as Program Enters Step Four

Forescout, a global cybersecurity leader and a key provider of cybersecurity solutions to the U.S. Department of Defense (DoD), announced today that it secured a new contract with the DoD as it enters year four of the highly successful Comply-to-Connect (C2C) program. The program’s next stage will be to configure delivered capabilities to enforce zero trust access principles across the DoD Information Network (DoDIN) enterprise and bring the DoD closer to the goals set forth in the Department’s Zero Trust Strategy.

As advocated by the Defense Information System Agency (DISA) C2C Program Management Office (PMO), the new contract also delivers additional capabilities to the C2C platform that revolutionize security of Operational Technology networks and integrates risk management and decision making into the existing C2C platform. This addition further positions the DoD to apply NIST zero trust principles to millions of devices across the enterprise. Implementation of zero trust principles using Forescout’s C2C capabilities is already being accomplished in some areas of the Army, via an initiative being taught at Fort Gordon school houses and referenced in Defense Acquisition University.

With the first three steps of the program – visibility, compliance assessment, and automated remediation – well underway, administrators can now use Forescout’s orchestration capabilities to manage policy enforcement points to create the desired effects on an individual user/device/access request basis. Additionally, Forescout’s continuous monitoring capabilities are at work to ensure connected devices don’t fall out of compliance due to files getting corrupted, simple administrative mistakes, or malicious adversarial actions, all of which occur daily on the DoDIN.

C2C is one of the largest government cybersecurity initiatives in the world delivering enterprise scale capabilities for managing cyber operational risk. With the program now in its fourth year, automated control of access to and within the DoDIN will ensure that each network user has the access necessary to achieve their mission without exposing other users to threats that could impact their ability to complete their mission.

“We are proud to once again be trusted by so many organizations to secure the backbone of their operations: the networks that connect everything,” said Barry Mainz, CEO, Forescout. “Each DoDIN user should have confidence that their slice of the network is secure and ready for them to accomplish their mission. That’s what we are delivering through C2C.”

Today, the Forescout platform provides comprehensive capabilities for the DoD’s C2C security framework that enables the critical first pillar of DISA’s zero trust program called Thunderdome. This includes:

  • Network-based discovery and classification of assets, including an expanding set of “unmanaged” assets that are unable to operate agents (C2C Steps 1 and 2)
  • Integration with other enterprise solutions such as Identity, Credential, and Access Management (ICAM); Security Information Event Management (SIEM); and Vulnerability Assessment products to automate compliance of the cybersecurity posture and establish trust for every connecting asset (C2C Step 3)
  • Orchestration of policy enforcement points across the infrastructure to enforce network access control and segmentation of assets as well as complete situational awareness of the network posture (C2C Steps 4 and 5)

“We look forward to introducing cloud-based advanced threat analysis tools into the C2C program’s portfolio of capabilities and adding further value on DoD’s zero trust journey,” added Mainz. “We’ve really just begun to unleash the power of our platform within the DoD. The best is still ahead.”

Additional Resources

About Forescout

Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats. www.forescout.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230914036853/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye